Seminars in Oncology
Volume 31, Issue 4 , Pages 450-464 , August 2004

Epidemiology of upper gastrointestinal malignancies

  • Katherine D. Crew

      Affiliations

    • Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    • K.D.C. is the recipient of a postdoctoral fellowship (T32 CA09529) and A.I.N. is the recipient of a K05 award (CA89155) from the National Cancer Institute.
    • ,
  • Alfred I. Neugut

      Affiliations

    • Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    • Corresponding Author InformationAddress reprint requests to Alfred I. Neugut, MD, PhD, New York-Presbyterian Hospital, 722 West 168th St, MSPH 725, New York, NY 10032 USA

References 

  1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54:1–13
  2. Blot WJ, Devesa SS, Kneller RW, et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287–1289
  3. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin North Am. 2002;11:235–256
  4. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1–9
  5. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma: An attempt at a histoloclinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49
  6. Munoz N, Correa P, Cuello C, et al.  Histological types of gastric carcinoma in high and low risk areas. Int J Cancer. 1968;3:809–818
  7. Kaneko S, Yoshimura T. Time trend anaylsis of gastric cancer incidence in Japan by histological types, 1975–1989. Br J Cancer. 2001;84:400–405
  8. Bosch A, Frias Z, Caldwell WL. Adenocarcinoma of the esophagus. Cancer. 1979;43:1557–1561
  9. Turnbull ADM, Goodner JT. Primary adenocarcinoma of the esophagus. Cancer. 1968;22:915–918
  10. Webb JN, Busuttil A. Adenocarcinoma of the esophagus and of the oesophagogastric junction. Br J Surg. 1978;65:475–479
  11. Institute NC . In: SEER Program Public Use Data Tapes, 1973–1999. Vol 2002:Bethesda, MD: DCCPS, Surveillance Research Program; 2002;
  12. Yang PC, Davis S. Incidence of cancer of the esophagus in the U.S. by histologic type. Cancer. 1988;61:612–617
  13. Pera M, Cameron AJ, Trastek VF, et al.  Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104:510–513
  14. Blot WJ, Devesa SS, Fraumeni JF. Continuing climb in rates of esophageal adenocarcinoma (An update). JAMA. 1993;270:1320; (letter)
  15. Jankowski J. CRC CancerStats (Oesophageal Cancer). London, UK: Cancer Research Campaign Press; 2001;
  16. Jemal A, Thomas A, Murray T, et al.  Cancer Statistics, 2002. CA Cancer J Clin. 2002;52:23–47
  17. Ries I, Kosary CL, Hankey B, et al.  Cancer Statistics Review 1973–1994. Bethesda, MD: Department of Health and Human Services; 1997; NIH Publications No. 97-2789.
  18. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas (Analysis of regional variation using the Cancer Incidence in Five Continents database). Int J Epidemiol. 2001;30:1415–1425
  19. Parkin D, Muir C, Whelan S, et al.  Cancer Incidence in Five Continents. Lyon, France: IARC Scientific Publications; 1992;
  20. Munoz N, Day NE. In: Esophageal cancer, in Cancer Epidemiology and Prevention. (ed 2).. New York, NY: Oxford University Press; 1996;p. 681–706
  21. Hansen S, Wig JN, Giercksky KE, et al.  Esophageal and gastric carcinoma in Norway 1958–1992 (Incidence time trend variability according to morphological subtypes and organ subsites). Int J Cancer. 1997;71:340–344
  22. Moller H. Incidence of cancer of the esophagus, cardia and stomach in Denmark. Eur J Cancer Prev. 1992;1:159–164
  23. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer. 1993;5:402–407
  24. Powell J, McConkey CC. The rising trend in esophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev. 1992;1:265–269
  25. Harrison SL, Goldacre MJ, Seagroatt V. Trends in registered incidence of oesophageal and stomach cancer in the Oxford region, 1974–88. Eur J Cancer Prev. 1992;1:271–274
  26. Levi F, La Vecchia C, Te VC. Descriptive epidemiology of adenocarcinoma of the cardia and distal stomach in the Swiss Canton of Vaud. Tumori. 1990;76:167–171
  27. Levi F, Randimbison L, La Vecchia C. Esophageal and gastric carcinoma in Vaud, Switzerland, 1967–1994. Int J Cancer. 1998;75:160–161
  28. Armstrong RW, Borman B. Trends in incidence rates of adenocarcinoma of the esophagus and gastric cardia in New Zealand, 1978–1992. Int J Epidemiol. 1996;25:941–947
  29. Lord RV, Law MG, Ward RL, et al.  Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol. 1998;13:356–362
  30. Thomas RJ, Lade S, Giles GG, et al.  Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust NZ J Surg. 1996;66:271–275
  31. Bollschweiler E, Wolfgarten E, Gutschow C, et al.  Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92:549–555
  32. Parkin DM, Whelan SL, Ferlay J, et al.  In: Cancer Incidence in Five Continents. vol VII:Lyon, France: International Agency for Research on Cancer; 1997;p. 822–823
  33. Nomura A. Stomach cancer. In:  Schottenfeld D,  Fraumeni JF editor. Cancer Epidemiology and Prevention. (ed 2).. New York, NY: Oxford University Press; 1996;p. 707–724
  34. In:  Kakizoe T editors. Cancer Statistics in Japan. Tokyo, Japan: Foundation for Promotion of Cancer Research; 1999; Tokyo, Japan
  35. Brown LM, Hoover R, Silverman D, et al.  Excess incidence of squamous cell esophageal cancer among US Black men (Role of social class and other risk factors). Am J Epidemiol. 2001;153:114–122
  36. Kalish RJ, Clancy PE, Orringer MB, et al.  Clinical epidemiologic and morphologic comparison between adenocarcinomas arising in Barrett’s esophageal mucosa and gastric cardia. Gastroenterology. 1984;86:461–467
  37. Rogers EL, Goldkind SF, Iseri OA, et al.  Adenocarcinoma of the lower esophagus. A disease primarily of white men with Barretts esophagus. J Clin Gastroenterol. 1986;8:613–618
  38. Wang HH, Antonioli DA, Goldman H. Comparative features of esophageal and gastric adenocarcinomas (Recent changes in type and frequency). Hum Pathol. 1986;17:482–487
  39. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26(suppl 15):2–8
  40. Chalasani N, Wo JM, Waring JP. Racial differences in the histology, location, and risk factors for esophageal cancer. J Clin Gastroenterol. 1998;26:11–13
  41. El-Serag HG, Mason AC, Petersen N, et al.  Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002;50:368–372
  42. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer. 2002;95:2096–2102
  43. Fielding JWL, Powell J, Allum WH, et al.  In: Cancer of the Stomach (Clinical Cancer Monographs. Vol 3:London, UK: Macmillan; 1989;
  44. IARC Unit of Descriptive Epidemiology . WHO cancer mortality databank. Cancer Mondial. 2001; www-dep.iarc.fr/ataava/globocan/who.htm
  45. Theuer CP, Kurosaki T, Ziogas A, et al.  Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates. Cancer. 2000;89:1883–1892
  46. Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–1277
  47. Feldman RA. Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori. In:  Achtman M,  Serbaum S editor. Helicobacter pylori (Molecular and Cellular Biology). Wymondham, UK: Horizon Scientific; 2001;p. 29–51
  48. International Agency for Research on Cancer . Schistosomes, liver flukes and Helicobacter pylori. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol 61.:Lyon, France: International Agency for Research on Cancer; 1994;
  49. The Eurogast Study Group . An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993;341:1359–1362
  50. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9:45–51
  51. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer (Epidemiology of an unplanned triumph). Epidemiol Rev. 1986;8:1–27
  52. Sipponen P, Kosunen TU, Valle J, et al.  Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol. 1992;45:319–323
  53. Hansson LE, Engstrand L, Nyren O, et al.  Helicobacter pylori infection (Independent risk indicator of gastric adenocarcinoma). Gastroenterology. 1993;105:1098–1103
  54. Hu PJ, Mitchell HM, Li YY, et al.  Association of Helicobacter pylori with gastric cancer and observations on the detection of this bacterium in gastric cancer cases. Am J Gastroenterol. 1994;89:1806–1810
  55. Kikuchi S, Wada O, Nakajima T, et al.  Research Group on Prevention of Gastric Carcinoma among Young Adults   Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Cancer. 1995;75:2789–2793
  56. Kokkola A, Valle J, Haapiainen R, et al.  Helicobacter pylori infection in young patients with gastric carcinoma. Scand J Gastroenterol. 1996;31:643–647
  57. Barreto-Zuniga R, Maruyama M, Kato Y, et al.  Significance of Helicobacter pylori infection as a risk factor in gastric cancer (serological and histological studies). J Gastroenterol. 1997;32:289–294
  58. Miehlke S, Hackelsberger A, Meining A, et al.  Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer. 1997;73:837–839
  59. Parsonnet J, Friedman GD, Vandersteen DP, et al.  Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131
  60. Nomura A, Stemmermann GN, Chyou PH, et al.  Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132–1136
  61. Forman D, Newell DG, Fullerton F, et al.  Association between infection with Helicobacter pylori and risk of gastric cancer (Evidence from a prospective investigation). Br Med J. 1991;302:1302–1305
  62. Nomura AMY, Stermmermann GN, Chyou PH. Gastric cancer among the Japanese in Hawaii. Jpn J Cancer Res. 1995;86:916–923
  63. Uemura N, Shiro K, Soichiro Y, et al.  Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789
  64. Kuipers EJ, Uyterlinde AM, Pena AS, et al.  Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345:1525–1528
  65. Valle J, Kekki M, Sipponen P, et al.  Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32 year follow up study. Scand J Gastroenterol. 1996;31:546–550
  66. Correa P. Helicobacter pylori and gastric cancer (State of the art). Cancer Epidemiol Biomarkers Prev. 1996;5:477–481
  67. Tomb JF, White O, Kerlavage AR, et al.  The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997;388:539–547
  68. Alm RA, Ling LS, Moir DT, et al.  Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 1999;397:176–180
  69. Peek RM, Miller GG, Tham KT, et al.  Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest. 1995;73:760–770
  70. Kuipers EJ, Perez-Perez GI, Meuwissen SG, et al.  Helicobacter pylori and atrophic gastritis (Importance of the cagA status). J Natl Cancer Inst. 1995;87:1777–1780
  71. Blaser MJ, Perez-Perez GI, Kleanthous H, et al.  Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55:2111–2115
  72. Parsonnet J, Friedman GD, Orentreich N, et al.  Risk for gastric cancer in people with CagA+ or CagA− Helicobacter pylori infection. Gut. 1997;40:297–301
  73. Nomura AMY, Lee J, Stermmermann GN, et al.  Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J Infect Dis. 2002;186:1138–1144
  74. Vicari JJ, Peek RM, Falk GW, et al.  The seroprevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 1998;115:50–57
  75. Loffeld RJFL, Werdmuller BFM, Kuster JG, et al.  Colonization with cagA positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett’s esophagus. Digestion. 2000;62:95–99
  76. Vaezi MF, Falk GW, Peek RM, et al.  CagA-positive strains of Helicobacter pylori may protect against Barrett’s esophagus. Am J Gastroenterol. 2000;95:2206–2211
  77. El-Omar EM, Carrington M, Chow WH, et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402
  78. Hansen S, Melby KK, Aase E, et al.  Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer (A nested case-control study). Scand J Gastroenterol. 1999;34:353–360
  79. Chow WH, Blaser MJ, Blot WJ, et al.  An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588–590
  80. Lagergren J, Bergstrom R, Lindgren A, et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  81. Chow WH, Finkle WD, McLaughin JK, et al.  The relation of gastroesophageal refulx disease and its treatment to adenocarcinoma of the esophagus and gastric cardia. JAMA. 1995;274:474–477
  82. Cameron AJ, Romero Y. Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma. Gut. 2000;46:754–755
  83. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110:614–621
  84. Shaheen NJ, Crosby MA, Bosymski EM, et al.  Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?. Gastroenterology. 2000;119:333–338
  85. Heath EI, Limburg PJ, Hawk ET, et al.  Adenocarcinoma of the esophagus (Risk factors and prevention). Oncology (Huntingt). 2000;14:507–514
  86. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am. 1997;26:487–494
  87. Conio M, Cameron AJ, Romero Y, et al.  Secular trends in the epidemiology and outcome of Barrett’s oesophagus in Olmsted County, Minnesota. Gut. 2001;48:304–309
  88. Cameron AJ, Zinsmeister AR, Ballard DJ, et al.  Prevalence of columnar-lined (Barrett’s) esophagus (Comparison of population-based clinical and autopsy findings). Gastroenterology. 1990;99:918–922
  89. Lagergren J, Bergstrom R, Adami HO, et al.  Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133:227–229
  90. Warburton-Timms VJ, Charlett A, Valori RM, et al.  The significance of cagA(+) Helicobacter pylori in reflux oesophagitis. Gut. 2001;49:341–346
  91. El-Serag HB, Sonnenberg A, Jamal MM, et al.  Corpus gastritis is protective against reflux oesophagitis. Gut. 1999;45:181–185
  92. Koike T, Ohara S, Sekine H, et al.  Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut. 2001;49:330–334
  93. Labenz J, Blum AL, Bayerdorffer E, et al.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442–1447
  94. Moayyedi P, Bardhan C, Young L, et al.  Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal relux disease. Gastroenterology. 2001;121:1120–1126
  95. Schwizer W, Thumshirn M, Dent J, et al.  Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease (A randomized controlled trial). Lancet. 2001;357:1738–1742
  96. Castellsague X, Munoz N, De Estefani E, et al.  Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer. 1999;82:654–657
  97. Bosetti C, Franceschi S, Levi F, et al.  Smoking and drinking cessation and the risk of oesophageal cancer. Br J Cancer. 2000;83:689–691
  98. Vaughan TL, Davis S, Kristal A, et al.  Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia (adenocarcinoma versus squamous cell carcinoma). Cancer Epidemiol Biomarkers Prev. 1995;4:85–92
  99. Lagergren J, Bergstron R, Lindgren A, et al.  The role of tobacco, snuff, and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer. 2000;85:340–346
  100. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721–732
  101. Gammon MD, Schoenberg JB, Ahsan H, et al.  Tobacco, alcohol and socioeconomic status and adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst. 1997;89:1277–1284
  102. Chao A, Thun MJ, Henley J, et al.  Cigarette smoking, use of other tobacco products and stomach cancer mortality in U.S. adults (The Cancer Prevention Study II). Int J Cancer. 2002;101:380–389
  103. Franceschi S, La Vecchia C. Alcohol and the risk of cancers of the stomach and colon-rectum. Dig Dis. 1994;12:276–289
  104. Hu J, Nyren O, Wolk A, et al.  Risk factors for oesophageal cancer in northeast China. Int J Cancer. 1994;57:38–46
  105. Bosetti C, La Vecchia C, Talamini R, et al.  Food groups and risk of squamous cell esophageal cancer in northern Italy. Int J Cancer. 2000;87:289–294
  106. Brown LM, Swanson CA, Gridley G, et al.  Adenocarcinoma of the esophagus (role of obesity and diet). J Natl Cancer Inst. 1995;87:104–109
  107. Zhang ZF, Kurtz RC, Yu GP, et al.  Adenocarcinomas of the esophagus and gastric cardia (The role of diet). Nutr Cancer. 1997;27:298–309
  108. Terry P, Lagergren J, Ye W, et al.  Inverse association between intake of cereal fiber and risk of gastric cardia cancer. Gastroenterology. 2001;120:387–391
  109. Hirohata T, Kono S. Diet/nutrition and stomach cancer in Japan. Int J Cancer. 1997;10(suppl):S34–S36
  110. Kobayashi M, Tsubono Y, Sasazuki S, et al.  Vegetables, fruit and risk of gastric cancer in Japan (A 10-year follow-up of the JPHC Study Cohort I). Int J Cancer. 2002;102:39–44
  111. McCullough ML, Robertson AS, Jacobs EJ, et al.  A prospective study of diet and stomach cancer mortality in United States men and women. Cancer Epidemiol Biomarkers Prev. 2001;10:1201–1205
  112. Kono S, Hirohata T. Nutrition and stomach cancer. Cancer Causes Control. 1996;7:41–55
  113. Buiatti E, Palli D, Decarli A, et al.  A case-control study of gastric cancer and diet in Italy. II. Association with nutrients. Int J Cancer. 1990;45:896–901
  114. La Vecchia C, Ferraroni M, D’Avanzo B, et al.  Selected micronutrient intake and the risk of gastric cancer. Cancer Epidemiol Biomarkers Prev. 1994;3:393–398
  115. Hansson LE, Nyren O, Bertstrom R, et al.  Nutrients and gastric cancer risk. A population-based case-control study in Sweden. Int J Cancer. 1994;57:638–644
  116. Setiawan VW, Zhang ZF, Yu GP, et al.  Protective effect of green tea on the risk of chronic gastritis and stomach cancer. Int J Cancer. 2001;92:600–604
  117. Tsubono Y, Nishino Y, Komatsu S, et al.  Green tea and the risk of gastric cancer in Japan. N Engl J Med. 2001;344:632–636
  118. Hoshiyama Y, Kawaguchi T, Miura Y, et al.  A prospective study of stomach cancer death in relation to green tea consumption in Japan. Br J Cancer. 2002;87:309–313
  119. Carroll KK. Obesity as a risk factor for certain types of cancer. Lipids. 1998;33:1055–1059
  120. Jacobsen BK, Njolstad I, Thune I, et al.  Increase in weight in all birth cohorts in a general population (The Tromso study, 1974–1994). Arch Intern Med. 2001;161:466–472
  121. Calle EE, Rodriguez C, Walker-Thurmond K, et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638
  122. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883–890
  123. Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr. 2002;132(suppl):3467S–3470S
  124. Chow WH, Blot WJ, Vaughan TL, et al.  Body mass index and risk of adenocarcinoma of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:105–150
  125. Kuczmarski RJ, Flegal KM, Campbell SM, et al.  Increasing prevalence of overweight among U.S. adults. JAMA. 1994;272:205–211
  126. Selikoff IJ, Hammond EC, Seidman H. Mortality experience of insulation workers in the United States and Canada, 1943–76. Ann NY Acad Sci. 1979;330:91–116
  127. Weiss N. Cancer in relation to occupational exposure to perchloroethylene. Cancer Causes Control. 1995;6:257–266
  128. Norell S, Ahblom A, Lipping H, et al.  Esophageal cancer and vulcanization work. Lancet. 1983;1:462–463
  129. Gustavisson P, Hogstedt C, Evanoff B. Increased risk of esophageal cancer among workers exposed to combustion products. Arch Environ Health. 1993;48:243–244
  130. Radiation Effects Research Foundation . Life Span Study Report 9, 1950–1978. Supplementary Tables. Hiroshima, Japan: Radiation Effects Research Foundation; 1981;
  131. Ahsan H, Neugut AI. Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med. 1998;128:114–117
  132. Li T, Lu ZM, Chen KN, et al.  Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of China. Carcinogenesis. 2001;22:929–934
  133. Shen ZY, Hu SP, Lu LC, et al.  Detection of human papillomavirus in esophageal carcinoma. J Med Virol. 2002;68:412–416
  134. Thompson DE, Mabuchi K, Ron E, et al.  Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958–1987. Radiat Res. 1994;137:S17–S67
  135. Palli D, Galli M, Caporaso NE, et al.  Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994;3:15–18
  136. La Vecchia C, Negri E, Franchescki S, et al.  A family history and the risk of stomach and colorectal cancer. Cancer. 1992;70:50–55
  137. Lissowska J, Groves FD, Sobin LH, et al.  Family history and risk of stomach cancer in Warsaw, Poland. Eur J Cancer Prev. 1999;8:223–227
  138. Hsing A, Hansson L, McLaughlin J, et al.  Pernicious anemia and subsequent cancer (A population based cohort study). Cancer. 1993;71:745–750
  139. Aird I, Bentall H. A relationship between cancer of stomach and ABO groups. Br J Med. 1953;1: 799–780
  140. Stalnikowicz R, Benbassat J. Risk of gastric cancer after gastric surgery for benign disorders. Arch Intern Med. 1990;150:2022–2026
  141. Levine PH, Stemmermann G, Lennette ET, et al.  Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr virus associated gastric adenocarcinoma. Int J Cancer. 1995;60:642–644
  142. Uemura Y, Tokunaga M, Arikawa J, et al.  A unique morphology of Epstein-Barr virus related early gastric carcinoma. Cancer Epidemiol Biomarkers Prev. 1994;3:607–611
  143. Shousha S, Luqmani YA. Epstein-Barr virus in gastric carcinoma and adjacent normal gastric and duodenal mucosa. J Clin Pathol. 1994;47:695–698
  144. Alberts SR, Cervantes A, van de Velde CJH. Gastric cancer (Epidemiology, pathology and treatment). Ann Oncol. 2003;14(suppl 2):ii31–ii36
  145. National Center for Health Statistics, Health, United States, 1996–1997 and Injury Chartbook. Hyatsville, MD: Public Health Service; 1997; DHHS Pub. No. (PHS) 97-1232.
  146. Blot WJ, Li JY, Taylor PR, et al.  Nutrition intervention trials in Linxian, China (Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population). J Natl Cancer Inst. 1993;85:1483–1492
  147. Varis KV, Taylor PR, Sipponen P, et al.  Gastric cancer and premalignant lesions in atrophic gastritis (A controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene). Scand J Gastroenterol. 1998;33:294–300
  148. Jacobs EJ, Connell CJ, McCullough ML, et al.  Vitamin C, vitamin E, and multivitamin supplement use and stomach cancer mortality in the Cancer Prevention Study II Cohort. Cancer Epidemiol Biomarkers Prev. 2002;11:35–41
  149. Mark SD, Liu SF, Li JY, et al.  The effect of vitamin and mineral supplementation on esophageal cytology (Results from the Linxian dysplasia trial). Int J Cancer. 1994;57:162–166
  150. Clark LC, Combos GF, Turnbull BW, et al.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin (A randomized controlled trial). JAMA. 1996;276:1957–1963
  151. Mark SD, Qiao YL, Dawsey SM, et al.  Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst. 2000;92:1753–1763
  152. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186
  153. Uemura N, Mukai T, Okamoto S, et al.  Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:639–642
  154. Correa P, Fontham ETH, Bravo JC, et al.  Chemoprevention of gastric dysplasia (randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy). J Natl Cancer Inst. 2000;92:1881–1888
  155. Sung JJY, San-rin L, Ching JYL, et al.  Atrophy and intestinal metaplasia one year after cure of H. pylori infection (A prospective, randomized study). Gastroenterology. 2000;119:7–14
  156. Sampliner RE. Practice guidelines on the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 1998;93:1028–1031
  157. Ye W, Chow WH, Lagergren J, et al.  Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121:1286–1293
  158. Spechler SJ, Lee E, Ahnen D, et al.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease (Follow-up of a randomized controlled trial). JAMA. 2001;285:2331–2338
  159. Triadafilopoulos G. Proton pump inhibitors for Barrett’s oesophagus. Gut. 2000;46:144–146
  160. Peters FTM, Ganesh S, Kuipers EJ, et al.  Endoscopic regression of Barrett’s oesophagus during omeprazole treatment (A randomized double blind study). Gut. 1999;45:489–494
  161. Hirota WK, Loughney TM, Lazas DJ, et al.  Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction (Prevalence and clinical data). Gastroenterology. 1999;116:277–285
  162. Reid BJ, Levine DS, Longton G, et al.  Predictors of progression to cancer in Barrett’s esophagus (Baseline histology and flow cytometry identify low- and high-risk patient subsets). Am J Gastroenterol. 2000;95:1669–1676
  163. Buttar NS, Wang KK, Sebo TJ, et al.  Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120:1630–1639
  164. Skacel M, Petras RE, Gramlich TL, et al.  The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95:3383–3387
  165. Montgomery E, Bronner MP, Goldblum JR, et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus (a reaffirmation). Hum Pathol. 2001;32:368–378
  166. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett’s oesophagus (Observational study). Br Med J. 2000;321:1252–1255
  167. Swisher SG, Deford L, Merriman KW, et al.  Effects of operative volume on morbidiy, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000;119:1126–1132
  168. van den Boogert J, van Hillegersberg R, Siersema PD, et al.  Endoscopic ablation therapy for Barrett’s esophagus with high-grade dysplasia (A review). Am J Gastroenterol. 1999;94:1153–1160
  169. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus (Follow-up in 100 patients). Gastrointest Endosc. 1999;49:1–7
  170. Inadomi JM, Sampliner R, Lagergren J, et al.  Screening and surveillance for Barrett’s esophagus in high-risk groups (A cost-utility analysis). Ann Intern Med. 2003;138:176–186
  171. Amonkar MM, Kalsekar ID, Boyer JG. The economic burden of Barrett’s esophagus in the Medicaid population. Ann Pharmacother. 2002;36:605–611
  172. Arguedas MR, Eloubeidi MA. Barrett’s esophagus (A review of the costs of the illness). Pharmacoeconomics. 2001;19:1003–1011
  173. Wright TA, Gray MR, Morris AI, et al.  Cost effectiveness of detecting Barrett’s cancer. Gut. 1996;39:574–579
  174. Streitz M, Ellis FH, Tilden RL, et al.  Endoscopic surveillance of Barrett’s esophagus (A cost-effectiveness comparison with mammographic surveillance for breast cancer). Am J Gastroenterol. 1998;93:911–915
  175. Guo HQ, Guan P, Shi HL, et al.  Prospective cohort study of comprehensive prevention to gastric cancer. World J Gastroenterol. 2003;9:432–436
  176. Kelley DJ, Mestre JR, Subbaramaiah K, et al.  Benzo [a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 1997;18:795–799
  177. Shirvani VN, Quatu-LaScar R, Kaur BS, et al.  Cyclooxygenase-2 expression in Barrett’s esophagus and adenocarcinoma (Ex vivo induction by bile salts and acid exposure). Gastroenterology. 2000;118:487–496
  178. Fu S, Ramanujam KS, Wong A, et al.  Increased expression and cellular localization of inducible nitric oxide synthase and cylcooxygenase-2 in Helicobacter pylori gastritis. Gastroenterology. 1999;116:1319–1329
  179. Kandil HM, Tanner G, Smalley W, et al.  Cyclooxygease-2 expression in Barrett’s esophagus. Dig Dis Sci. 2001;46:785–789
  180. Ristimaki A, Honkanen N, Jankala H, et al.  Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280
  181. Buttar NS, Wang KK, Leonpovich O, et al.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology. 2002;122:1101–1112
  182. Farrow DC, Vaughan TL, Hansten PD, et al.  Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97–102
  183. Corley DA, Kerlikowske K, Verma R, et al.  Protective association of aspirin/NSAIDs and esophageal cancer (Systematic review and meta-analysis). Gastroenterology. 2003;124:246–248
  184. Gupta R, DuBois R. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett’s esophagus. J Natl Cancer Inst. 2002;94:406–407

PII: S0093-7754(04)00242-8

doi: 10.1053/j.seminoncol.2004.04.021

Seminars in Oncology
Volume 31, Issue 4 , Pages 450-464 , August 2004

Article Tools

* Image Usage & Resolution